News Releases

January 30, 2020
Synlogic Appoints Dr. Michael Burgess to its Board of Directors
CAMBRIDGE, Mass. , Jan. 30, 2020 /PRNewswire/ --  Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess ,   M.B., Ch.B., Ph.D., president of research and...
January 9, 2020
Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs
– First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020 – – Expansion of pipeline with new preclinical programs in secondary hyperoxaluria and maple syrup urine disease (MSUD) – – Phase 2 clinical trial of solid formulation of SYNB1618 in patients with...
December 11, 2019
Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development
– Company expects to initiate Phase 2 clinical trial in patients with phenylketonuria in 1H 2020 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 11, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines,...
November 25, 2019
Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 25, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference at 11:30 am ET on Thursday,...
November 12, 2019
Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results
–SYNB1618 solid oral bridging study ongoing and SYNB1891 immuno-oncology study open – – Company ends 3Q2019 with approximately $139 million in cash, cash equivalents and investments supporting projected runway through 2021 – – Management to host conference call and webcast at 5:00 pm ET today –...
November 5, 2019
Synlogic Announces Third Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its third quarter 2019 financial results after the market...
September 30, 2019
Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 4:15...
September 4, 2019
Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the following two new additions to its senior leadership team: This press release...
September 4, 2019
Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)
– Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria – – Synlogic has initiated a bridging study of a new solid formulation of SYNB1618 to inform dosing in future efficacy study – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep....
August 20, 2019
Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia
– SYNB1020 well tolerated in Phase 1b/2a study, but did not lower blood ammonia in patients with cirrhosis – – Company will focus resources on advancement of SYNB1618, SYNB1891 and new early development programs – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2019-- Synlogic, Inc....
August 8, 2019
Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Scott Plevy , M.D., Synlogic’s chief scientific officer, will provide a corporate update at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 9:45 am ET , in New York City ....
August 8, 2019
Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates
– Strong balance sheet supports clinical advancement of lead and emerging Synthetic Biotic ™ programs – –Bridging study to evaluate solid oral formulation of SYNB1618 open and recruiting healthy volunteers – – Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass....
Displaying 49 - 60 of 146